GLP-1 and Its Role in Glycogen Production: A Narrative Review

QR Code

GLP-1 and Its Role in Glycogen Production: A Narrative Review

Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM). GLP-1 receptor agonis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joseph Lotosky, Xavier Jean, Anungoo Altankhuyag, Saqib Khan, Ashley Bernotas, Alireza Sharafshah, Kenneth Blum, Alan Posner, Panayotis K. Thanos
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	glucagon-like peptide-1 (GLP-1) glucagon-like peptide-1 receptor (GLP-1R) glucagon-like peptide-1 receptor agonist (GLP-1RA) glycogen glycogenesis thermogenesis
Online Access:	https://www.mdpi.com/2227-9059/13/7/1610
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting
by: Bárbara Ferreira, et al.
Published: (2025-06-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Addressing weight loss management in obese gout patients: guidance for future trials
by: Robin Christensen, et al.
Published: (2024-11-01)

Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
by: Zhixuan Xie, et al.
Published: (2025-07-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
by: Areesha Moiz, et al.
Published: (2025-08-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

GLP-1R as a potential link between diabetes and Alzheimer’s disease
by: Shujun Li, et al.
Published: (2025-07-01)

The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
by: Michael Nunns, et al.
Published: (2025-06-01)

Gut Hormones and Inflammatory Bowel Disease
by: Jonathan Weng, et al.
Published: (2025-07-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
by: Laura Patton, et al.
Published: (2025-07-01)

The main directions and prospects in polycystic ovary syndrome treatment
by: A. N. Useinova, et al.
Published: (2021-12-01)

Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide
by: A. S. Ametov, et al.
Published: (2024-01-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
by: M. A. Druzhilov, et al.
Published: (2022-05-01)

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity
by: A. S. Ametov, et al.
Published: (2025-03-01)

Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?
by: Dan Kaufmann, et al.
Published: (2025-06-01)

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
by: Bisma Fatima Hammad, et al.
Published: (2025-07-01)

Alleviation of Adipose Tissue Inflammation and Obesity Suppression by a Probiotic Strain That Induces GLP-1 Secretion
by: A-Ram Kim, et al.
Published: (2025-05-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01)

Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: A secondary cross-sectional analysis
by: Brittany V.B. Johnson, et al.
Published: (2025-12-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Efficacy of liraglutide in patients with metabolic-associated steatotic liver disease in type 2 diabetes mellitus
by: Yu.M. Stepanov, et al.
Published: (2025-06-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
by: Tyler S. Oesterle, et al.
Published: (2025-06-01)

Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
by: Velimir Altabas, et al.
Published: (2025-06-01)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01)

Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines
by: Safi G. Alqatari, et al.
Published: (2025-07-01)

A thermogenic botanical composition containing Citrus aurantifolia fruit rind and Theobroma cacao seed extracts improves body composition in overweight adults: a clinical investigation
by: Amulya Chadalavada, et al.
Published: (2025-06-01)